{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Mutated+Non-small+Cell+Lung+Cancer+Patients", "query": { "condition": "EGFR Mutated Non-small Cell Lung Cancer Patients" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 108, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Mutated+Non-small+Cell+Lung+Cancer+Patients&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T16:47:32.410Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03786692", "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Carcinoma of Lung, TNM Stage 4" ], "interventions": [ { "name": "Arm A", "type": "DRUG" }, { "name": "Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2019-09-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786692" }, { "nct_id": "NCT02349633", "title": "Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "PF-06747775", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-05-14", "completion_date": "2020-05-28", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 7, "location_summary": "La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02349633" }, { "nct_id": "NCT02947386", "title": "Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EGFR Gene Mutation", "Recurrent Non-Small Cell Lung Carcinoma", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nimotuzumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2017-06-29", "completion_date": "2022-09-08", "has_results": false, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947386" }, { "nct_id": "NCT01802632", "title": "AZD9291 First Time In Patients Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Non Small Cell Lung Cancer", "Advanced (Inoperable) Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD9291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 603, "start_date": "2013-03-04", "completion_date": "2023-12-11", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 7, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802632" }, { "nct_id": "NCT02151981", "title": "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anticancer Treatment" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Cross-over to Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 421, "start_date": "2014-08-04", "completion_date": "2023-12-15", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 21, "location_summary": "Anaheim, California • Orange, California • Santa Rosa, California + 18 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02151981" }, { "nct_id": "NCT04959981", "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non-squamous Non-small-cell Lung Cancer" ], "interventions": [ { "name": "ERAS-007", "type": "DRUG" }, { "name": "ERAS-601", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Erasca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 24, "start_date": "2021-09-02", "completion_date": "2023-04-27", "has_results": false, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 11, "location_summary": "Duarte, California • Orange, California • Santa Monica, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04959981" }, { "nct_id": "NCT05668988", "title": "A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "sunvozertinib", "type": "DRUG" }, { "name": "Pemetrexed+carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2022-12-13", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 14, "location_summary": "Glendale, California • Vallejo, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Margate", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668988" }, { "nct_id": "NCT02451852", "title": "AZD9291 US Expanded Access Program", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "EGFR T790M Mutation Positive NSCLC" ], "interventions": [ { "name": "AZD9291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 32, "location_summary": "Anaheim, California • Beverly Hills, California • Burbank, California + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451852" }, { "nct_id": "NCT04036682", "title": "A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "EGFR Exon 20 Mutation" ], "interventions": [ { "name": "CLN-081", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cullinan Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2019-10-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 18, "location_summary": "Anaheim, California • Duarte, California • Irvine, California + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04036682" }, { "nct_id": "NCT05493501", "title": "Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Aumolertinib monotherapy", "type": "DRUG" }, { "name": "Osimertinib monotherapy", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EQRx International, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-12-14", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-07-23T16:47:32.410Z", "location_count": 8, "location_summary": "Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05493501" } ] }